Chemomab Therapeutics Ltd. Research and Development Expense
Chemomab Therapeutics Ltd. (CMMB) reported Research and Development Expense of $5.83 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-03-23
- Chemomab Therapeutics Ltd. research and development expense for the quarter ending 2024-06-30 was $2.93M, a 41.67% decline year-over-year.
- Chemomab Therapeutics Ltd. research and development expense for the quarter ending 2023-06-30 was $5.02M, a 72.27% increase year-over-year.
- Chemomab Therapeutics Ltd. research and development expense for the quarter ending 2023-03-31 was $6.89M, a 150.89% increase year-over-year.
- Chemomab Therapeutics Ltd. research and development expense for the quarter ending 2022-12-31 was $5.89M, a 147.38% increase year-over-year.
- Chemomab Therapeutics Ltd. research and development expense for fiscal 2020 was $4.68M, a 64.79% decline from fiscal 2019.
- Chemomab Therapeutics Ltd. research and development expense for fiscal 2019 was $13.30M, a 77.04% increase from fiscal 2018.
- Chemomab Therapeutics Ltd. research and development expense for fiscal 2018 was $7.51M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $5.83M 20-F · filed 2026-03-23 | |||||||
| 2025-06-30 | $3.78M 6-K · filed 2025-08-14 | |||||||
| 2024-12-31 | $11.33M 20-F · filed 2026-03-23 | |||||||
| 2024-06-30 | $2.93M 6-K · filed 2024-08-21 | $6.08M 6-K · filed 2025-08-14 | ||||||
| 2023-12-31 | $18.38M 20-F · filed 2026-03-23 | |||||||
| 2023-06-30 | $5.02M 6-K · filed 2024-08-21 | $11.91M 6-K · filed 2024-08-21 | $17.80M derived: sum of 3 quarters · filed 2025-04-04 | $23.23M derived: sum of 4 quarters · filed 2025-04-04 | ||||
| 2023-03-31 | $6.89M 10-Q · filed 2023-05-11 | $12.78M derived: sum of 2 quarters · filed 2025-04-04 | $18.20M derived: sum of 3 quarters · filed 2025-04-04 | $21.12M derived: sum of 4 quarters · filed 2025-04-04 | ||||
| 2022-12-31 | $5.89M derived: 20-F 12 month − 10-Q 9 month · filed 2025-04-04 | $11.32M derived: sum of 2 quarters · filed 2025-04-04 | $14.23M derived: sum of 3 quarters · filed 2025-04-04 | $16.98M 20-F · filed 2025-04-04 | ||||
| 2022-09-30 | $5.42M 10-Q · filed 2022-11-10 | $8.34M derived: sum of 2 quarters · filed 2023-08-14 | $11.08M 10-Q · filed 2022-11-10 | $13.46M derived: sum of 4 quarters · filed 2024-03-28 | ||||
| 2022-06-30 | $2.91M 6-K · filed 2023-08-14 | $5.66M 6-K · filed 2023-08-14 | $8.04M derived: sum of 3 quarters · filed 2024-03-28 | $9.53M derived: sum of 4 quarters · filed 2024-03-28 | ||||
| 2022-03-31 | $2.75M 10-Q · filed 2023-05-11 | $5.13M derived: sum of 2 quarters · filed 2024-03-28 | $6.62M derived: sum of 3 quarters · filed 2024-03-28 | $7.92M derived: sum of 4 quarters · filed 2024-03-28 | ||||
| 2021-12-31 | $2.38M derived: 20-F 12 month − 10-Q 9 month · filed 2024-03-28 | $3.87M derived: sum of 2 quarters · filed 2024-03-28 | $5.18M derived: sum of 3 quarters · filed 2024-03-28 | $6.33M 20-F · filed 2024-03-28 | ||||
| 2021-09-30 | $1.49M 10-Q · filed 2022-11-10 | $2.79M derived: sum of 2 quarters · filed 2022-11-10 | $3.95M 10-Q · filed 2022-11-10 | $5.21M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $1.31M 10-Q · filed 2022-08-12 | $2.46M 10-Q · filed 2022-08-12 | $3.72M derived: sum of 3 quarters · filed 2022-08-12 | $4.75M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $1.16M 10-Q · filed 2022-05-12 | $2.41M derived: sum of 2 quarters · filed 2022-05-12 | $3.44M derived: sum of 3 quarters · filed 2022-05-12 | $4.29M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $2.29M derived: sum of 2 quarters · filed 2022-03-30 | $3.13M derived: sum of 3 quarters · filed 2022-03-30 | $4.68M 10-K · filed 2022-03-30 | $3.78M 10-K · filed 2021-03-09 | |||
| 2020-09-30 | $1.03M 10-Q · filed 2021-11-12 | $1.25M 10-Q · filed 2020-11-16 | $1.88M derived: sum of 2 quarters · filed 2021-11-12 | $3.43M 10-Q · filed 2021-11-12 | $3.61M 10-Q · filed 2020-11-16 | $4.46M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | $847.00K 10-Q · filed 2021-08-13 | $1.31M 10-Q · filed 2020-08-14 | $2.40M 10-Q · filed 2021-08-13 | $2.36M 10-Q · filed 2020-08-14 | $3.43M derived: sum of 3 quarters · filed 2021-08-13 | $8.99M derived: sum of 4 quarters · filed 2021-08-13 | ||
| 2020-03-31 | $1.55M 10-Q · filed 2021-05-13 | $1.05M 10-Q · filed 2020-05-07 | $2.58M derived: sum of 2 quarters · filed 2021-05-13 | $8.14M derived: sum of 3 quarters · filed 2021-05-13 | $10.72M derived: sum of 4 quarters · filed 2021-05-13 | |||
| 2019-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $6.59M derived: sum of 2 quarters · filed 2021-03-09 | $9.17M derived: sum of 3 quarters · filed 2021-03-09 | $13.30M 10-K · filed 2021-03-09 | ||||
| 2019-09-30 | $5.57M 10-Q · filed 2020-11-16 | $8.14M derived: sum of 2 quarters · filed 2020-11-16 | $12.28M 10-Q · filed 2020-11-16 | |||||
| 2019-06-30 | $2.58M 10-Q · filed 2020-08-14 | $6.71M 10-Q · filed 2020-08-14 | ||||||
| 2019-03-31 | $4.13M 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $7.51M 10-K · filed 2020-03-17 |